Regular Statin Use and Incidence of Postendoscopic Retrograde Cholangiopancreatography Pancreatitis
Conclusions: Regular statin use was not shown to be protective against PEP. A further investigation is warranted before this medication is tested in prospective randomized trials.
CONCLUSIONS: Our meta-analysis seems to suggest the non-superiority of chronic statin therapy in preventing post-ERCP pancreatitis. PMID: 32993442 [PubMed - as supplied by publisher]
Authors: Facciorusso A, Buccino VR, Tonti P, Sacco R PMID: 32462964 [PubMed - as supplied by publisher]
One of the most feared complications of endoscopic retrograde cholangiopancreatography (ERCP), with an incidence of 3.5 to 15%, is post ERCP pancreatitis (PEP). Given the role of statins in the reduction of sy...
Purpose of review The present article will focus in pharmacologic agents that have been studied to improve acute pancreatitis outcomes, and to prevent the disease at different levels. Recent findings Too little and too much early fluid resuscitation can be harmful. The optimal volume, rate, and duration of intravenous fluid therapy is still unknown. Nonopioid analgesics should be the first line of analgesia in patients with acute pancreatitis. A few pharmacologic agents evaluated in acute pancreatitis have resulted in positive pilot trials; however, larger randomized clinical trials (RCTs) are needed before final conc...
Acute pancreatitis (AP) is the most common complication after endoscopic retrograde cholangiopancreatography (ERCP). Statins have been traditionally associated to an increased risk of AP, however, recent evidence suggests that statins may have a protective role against this disease.
Mahmud Mahamid, Abdulla Watad, Nicola L. Bragazzi, Dov Wengrower, Julie Wolff, Dan Livovsky, Howard Amital, Mohammad Adawi, Eran Goldin
Objectives Acute Pancreatitis is the most frequent complication of Endoscopic Retrograde Cholangiopancreatography (ERCP). Some prophylactic strategies have been investigated to prevent it, such as the use of pancreatic stents or the use of peri-procedural NSAIDs; the incidence of Post-ERCP Acute Pancreatitis (PEP) in patients consuming aminosalicylic acid (ASA), a NSAID, is unclear. Statins are widely used lipid-lowering drugs and recent studies suggest that chronic statin intake may be associated to a lower incidence of acute pancreatitis.
Background: There is evidence from epidemiological studies that statins are associated to a decreased risk of acute pancreatitis (AP). Nonsteroidal anti-inflammatory drugs (NSAIDs) are currently used for the prevention of post-ERCP AP. We hypothesized that both drugs are associated to a decreased risk for moderate-to- severe AP (MTSAP).
Background: An epidemiological study suggested that statins could decrease the incidence of acute pancreatitis (AP).
Introduction: An epidemiological study suggested that statins could decrease the incidence of acute pancreatitis (AP).